{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T11:39:02Z","timestamp":1774265942050,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12969-019-0355-0","type":"journal-article","created":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T11:02:44Z","timestamp":1564052564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5545-2501","authenticated-orcid":false,"given":"Cecilia","family":"Bava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Mongelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Pistorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Bertamino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Bracciolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Dalpr\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Dav\u00ec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Lanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Muratore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Pederzoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Rosina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Schiappapietra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Suffia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Varnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Verazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Giancane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Consolaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Ravelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,25]]},"reference":[{"key":"355_CR1","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","volume":"369","author":"A Ravelli","year":"2007","unstructured":"Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369:767\u201378.","journal-title":"Lancet"},{"key":"355_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0889-857X(02)00019-4","volume":"28","author":"ML Miller","year":"2002","unstructured":"Miller ML, LeBovidge J, Feldman B. Health-related quality of life in children with arthritis. Rheum Dis Clin N Am. 2002;28:493\u2013501.","journal-title":"Rheum Dis Clin N Am"},{"key":"355_CR3","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1097\/00002281-200309000-00014","volume":"15","author":"HI Brunner","year":"2003","unstructured":"Brunner HI, Giannini EH. Health-related quality of life in children with rheumatic diseases. Curr Opin Rheumatol. 2003;15:602\u201312.","journal-title":"Curr Opin Rheumatol"},{"key":"355_CR4","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/art.24202","volume":"59","author":"N Solari","year":"2008","unstructured":"Solari N, Viola S, Pistorio A, Magni-Manzoni S, Vitale R, Ruperto N, et al. Assessing current outcomes of juvenile idiopathic arthritis: a cross-sectional study in a tertiary center sample. Arthritis Rheum. 2008;59:1571\u20139.","journal-title":"Arthritis Rheum"},{"key":"355_CR5","doi-asserted-by":"publisher","first-page":"628","DOI":"10.3899\/jrheum.080560","volume":"36","author":"A Magnani","year":"2009","unstructured":"Magnani A, Pistorio A, Magni-Manzoni S, Falcone A, Lombardini G, Bandeira M, et al. Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. J Rheumatol. 2009;36:628\u201334.","journal-title":"J Rheumatol"},{"key":"355_CR6","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/art.1780390412","volume":"39","author":"JF Fries","year":"1996","unstructured":"Fries JF, Williams CA, Morfeld D, Singh G, Sibley J. Reduction of long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum. 1996;39:616\u201322.","journal-title":"Arthritis Rheum"},{"key":"355_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","volume":"364","author":"C Grigor","year":"2004","unstructured":"Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control of rheumatoid arthritis (the TICORA study): a single-blind randomized controlled trial. Lancet. 2004;364:263\u20139.","journal-title":"Lancet"},{"key":"355_CR8","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/acr.21973","volume":"65","author":"A Consolaro","year":"2013","unstructured":"Consolaro A, Ravelli A. It is worth including assessment of disease activity state in juvenile arthritis clinical trials. Arthritis Care Res. 2013;65:1207\u201310.","journal-title":"Arthritis Care Res"},{"key":"355_CR9","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrrheum.2014.212","volume":"11","author":"C Hinze","year":"2015","unstructured":"Hinze C, Gohar F, Foell D. Management of juvenile idiopathic arthritis: hitting the target. Nat Rev Rheumatol. 2015;11:290\u2013300.","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"355_CR10","first-page":"157","volume":"30","author":"A Consolaro","year":"2012","unstructured":"Consolaro A, Negro G, Lanni S, Solari N, Martini A, Ravelli A. Toward a treat-to-target approach in the management of juvenile idiopathic arthritis. Clin Exp Rheumatol. 2012;30(4 Suppl 73):157\u201362.","journal-title":"Clin Exp Rheumatol"},{"key":"355_CR11","first-page":"1830","volume":"27","author":"A Ravelli","year":"2000","unstructured":"Ravelli A, Martini A. Methotrexate in juvenile idiopathic arthritis: answers and questions. J Rheumatol. 2000;27:1830\u20133.","journal-title":"J Rheumatol"},{"issue":"5 Suppl 61","key":"355_CR12","first-page":"122","volume":"28","author":"R Guti\u00e9rrez-Su\u00e1rez","year":"2010","unstructured":"Guti\u00e9rrez-Su\u00e1rez R, Burgos-Vargas R. The use of methotrexate in children with rheumatic diseases. Clin Exp Rheumatol. 2010;28(5 Suppl 61):122\u20137.","journal-title":"Clin Exp Rheumatol"},{"key":"355_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1546-0096-12-51","volume":"12","author":"EHP Van Dijkhuizen","year":"2014","unstructured":"Van Dijkhuizen EHP, Wulffraat N. Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review. Pediatr Rheumatol Online J. 2014;12:51.","journal-title":"Pediatr Rheumatol Online J"},{"key":"355_CR14","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1056\/NEJM199204163261602","volume":"326","author":"EH Giannini","year":"1992","unstructured":"Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.a.-U.S.S.R. double-blind, placebo-controlled trial. N Engl J Med. 1992;326:1043\u20139.","journal-title":"N Engl J Med"},{"key":"355_CR15","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/art.20288","volume":"50","author":"N Ruperto","year":"2004","unstructured":"Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004;50:2191\u2013201.","journal-title":"Arthritis Rheum"},{"key":"355_CR16","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1136\/ard.2007.073445","volume":"67","author":"M Bartoli","year":"2008","unstructured":"Bartoli M, Tar\u00f2 M, Magni-Manzoni S, Pistorio A, Traverso F, Viola S. The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Ann Rheum Dis. 2008;67:370\u20134.","journal-title":"Ann Rheum Dis"},{"key":"355_CR17","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2010.375","volume":"303","author":"D Foell","year":"2010","unstructured":"Foell D, Wulffraat N, Wedderburn LR, Wittkowski H, Frosch M, Gerss J, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA. 2010;303:1266\u201373.","journal-title":"JAMA"},{"key":"355_CR18","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3899\/jrheum.131503","volume":"41","author":"CA Wallace","year":"2014","unstructured":"Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O\u2019Neil KM, Zeft AS, et al. Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors. J Rheumatol. 2014;41:1163\u201370.","journal-title":"J Rheumatol"},{"issue":"1","key":"355_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/annrheumdis-2018-213902","volume":"78","author":"Petra Hissink Muller","year":"2018","unstructured":"Hissink Muller P,\u00a0\u00a0Brinkman DMC,\u00a0\u00a0Schonenberg-Meinema D, van den Bosch WB,\u00a0Koopman-Keemink Y,\u00a0\u00a0Brederije ICJ, et al.\u00a0Treat to target (drug-free)\u00a0inactive\u00a0disease\u00a0in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial. Ann Rheum Dis. 2019;78:51\u201359.","journal-title":"Annals of the Rheumatic Diseases"},{"key":"355_CR20","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1542\/peds.100.6.994","volume":"100","author":"BS Gottlieb","year":"1997","unstructured":"Gottlieb BS, Keenan GF, Lu T, Ilowite NT. Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis. Pediatrics. 1997;100:994\u20137.","journal-title":"Pediatrics"},{"issue":"5 Suppl 31","key":"355_CR21","first-page":"89","volume":"21","author":"A Ravelli","year":"2003","unstructured":"Ravelli A, Martini A. Early predictors of outcome in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2003;21(5 Suppl 31):89\u201393.","journal-title":"Clin Exp Rheumatol"},{"key":"355_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1546-0096-12-35","volume":"12","author":"M Albarouni","year":"2014","unstructured":"Albarouni M, Becker I, Horneff G. Predictors of response to methotrexate in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2014;12:35.","journal-title":"Pediatr Rheumatol Online J"},{"key":"355_CR23","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1136\/annrheumdis-2017-211968","volume":"77","author":"J Klotsche","year":"2018","unstructured":"Klotsche J, Minden K, Niewerth M, Horneff G. Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA. Ann Rheum Dis. 2018;77:996\u20131002.","journal-title":"Ann Rheum Dis"},{"key":"355_CR24","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass D, Goldenberg J, et al. International league of associations of rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390\u20132.","journal-title":"J Rheumatol"},{"key":"355_CR25","first-page":"2290","volume":"31","author":"CA Wallace","year":"2004","unstructured":"Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31:2290\u20134.","journal-title":"J Rheumatol"},{"key":"355_CR26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/acr.20460","volume":"63","author":"T Beukelman","year":"2011","unstructured":"Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63:465\u201382.","journal-title":"Arthritis Care Res"},{"key":"355_CR27","first-page":"774","volume":"28","author":"C Scott","year":"2010","unstructured":"Scott C, Meiorin S, Filocamo G, Lanni S, Valle M, Martinoli C, et al. A reappraisal of intra-articular corticosteroid therapy in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2010;28:774\u201381.","journal-title":"Clin Exp Rheumatol"},{"key":"355_CR28","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1002\/art.34343","volume":"64","author":"CA Wallace","year":"2011","unstructured":"Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O'Neil KM, Zeft AS, et al. Childhood arthritis and rheumatology research Alliance. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2011;64:2012\u201321.","journal-title":"Arthritis Rheum"},{"key":"355_CR29","first-page":"819","volume":"77","author":"A Ravelli","year":"2018","unstructured":"Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77:819\u201328.","journal-title":"Ann Rheum Dis"},{"key":"355_CR30","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S0140-6736(17)30065-X","volume":"389","author":"A Ravelli","year":"2017","unstructured":"Ravelli A, Dav\u00ec S, Bracciolini G, Pistorio A, Consolaro A, Van Dijkhuizen EHP, et al. Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial. Lancet. 2017;389:909\u201316.","journal-title":"Lancet"},{"key":"355_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/B978-0-323-24145-8.00016-8","volume-title":"Textbook of pediatric rheumatology","author":"F De Benedetti","year":"2016","unstructured":"De Benedetti F, Schneider R. Systemic juvenile idiopathic arthritis. In: Petty RE, Laxer RM, Lindsley CB, Wedderburn LR, editors. Textbook of pediatric rheumatology. 7th ed. Philadelphia: Elsevier; 2016. p. 205\u201316.","edition":"7"},{"key":"355_CR32","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1136\/ard.2009.120840","volume":"69","author":"I Vilca","year":"2010","unstructured":"Vilca I, Munitis PG, Pistorio A, Ravelli A, Buoncompagni A, Bica B, et al. Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial. Ann Rheum Dis. 2010;69:1479\u201383.","journal-title":"Ann Rheum Dis"},{"key":"355_CR33","first-page":"297","volume":"9","author":"F Halle","year":"1991","unstructured":"Halle F, Prieur AM. Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype. Clin Exp Rheumatol. 1991;9:297\u2013302.","journal-title":"Clin Exp Rheumatol"},{"key":"355_CR34","doi-asserted-by":"publisher","first-page":"6","DOI":"10.24953\/turkjped.2017.01.002","volume":"59","author":"ED Batu","year":"2017","unstructured":"Batu ED, S\u00f6nmez HE, G\u00fclhan B, Ar\u0131c\u0131 ZS, Topalo\u011flu R, Bilginer Y. Predictors of methotrexate response in Turkish children with oligoarticular and polyarticular juvenile idiopathic arthritis. Turk J Pediatr. 2017;59:6\u201312.","journal-title":"Turk J Pediatr"},{"key":"355_CR35","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1136\/annrheumdis-2011-200942","volume":"71","author":"M Bulatovi\u0107","year":"2012","unstructured":"Bulatovi\u0107 M, Heijstek MW, Van Dijkhuizen EHP, Wulffraat NM, Pluijm SMF, De Jonge R. Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis. Ann Rheum Dis. 2012;71:1484\u20139.","journal-title":"Ann Rheum Dis"},{"key":"355_CR36","first-page":"1574","volume":"22","author":"A Ravelli","year":"1995","unstructured":"Ravelli A, Viola S, Ramenghi B, Aramini L, Ruperto N, Martini A. Frequency of relapse after discontinuation of methotrexate therapy for clinical remission in juvenile rheumatoid arthritis. J Rheumatol. 1995;22:1574\u20136.","journal-title":"J Rheumatol"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-019-0355-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12969-019-0355-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-019-0355-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T23:04:59Z","timestamp":1595545499000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-019-0355-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,25]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["355"],"URL":"https:\/\/doi.org\/10.1186\/s12969-019-0355-0","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,25]]},"assertion":[{"value":"12 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the ethics committee of the Istituto G. Gaslini, Genoa, Italy.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AR has received grant support and\/or speaking or consultant fees from Alfa sigma, Angelini, AbbVie, Bristol-Myers Squibb, Novartis, Pfizer, Reckitt Benckiser, Roche, and Johnson & Johnson; AC reports personal fees from AbbVie and Alfasigma and non-financial support from Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}